Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Lam Research, ASML Lead Surge In Revenue From China Despite US Trade Curbs

Published 17/11/2023, 13:39
Updated 17/11/2023, 14:40
Lam Research, ASML Lead Surge In Revenue From China Despite US Trade Curbs

Benzinga - by Anusuya Lahiri, Benzinga Editor.

Leading chipmaking equipment manufacturers are experiencing a surge in revenue from China as the country stockpiles equipment to counter U.S. trade restrictions on advanced semiconductors.

In the most recent quarter, significant chip suppliers of fabrication machinery obtained more than 40% of their revenue from Chinese customers.

Also, the recent tightening of U.S. export restrictions on advanced chip technology has not yet resulted in reduced sales to China for equipment manufacturers. It may have accelerated orders.

Also Read: Nvidia Likely to Outperform in Data Center and Gaming Segments: Goldman Sachs Analyst

  • Lam Research Corp (NASDAQ: LRCX) generated nearly half of its revenue from China, Bloomberg reports.
  • Tokyo Electron Ltd. also hit a record in the share of its shipments to China.
  • Despite a ban on shipping its most advanced systems to China, ASML Holding NV (NASDAQ: ASML) saw a high proportion of its revenue come from Chinese sales.
  • Applied Materials Inc (NASDAQ: AMAT) reported significant China sales in the October quarter, expecting elevated sales in the current period. The company anticipates China's share gradually returning to its typical 30% level over time.
What's Next

Furthermore, a U.S. criminal investigation into Applied Materials for alleged violations of export restrictions to China. The case has caused concerns in the industry, affecting the company's stock and its peers, including KLA Corp (NASDAQ: KLAC) and Lam.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.